Erlotinib, a small molecule tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) pathway, is the only non-cytotoxic agent approved for the treatment of pancreatic cancer; however, it is seldom utilized due to its marginal benefit in this disease. Here, EGFR is linked to familial pancreatic carcinoma.